Treating prostate cancer without major side effects

Metastatic castration-resistant prostate cancer can be difficult to treat, but advances in technology might provide a solution

1:33 PM

Author | Valerie Goodwin

cancer cell blue yellow
Jacob Dwyer, Justine Ross, Michigan Medicine

Within the last few years, nuclear medicine has added to cutting edge treatment options for cancer. 

One of the latest advancements is the use of a treatment called Pluvicto to treat metastatic castration-resistant prostate cancer.

Metastatic castration-resistant prostate cancer can’t be controlled with hormone therapy and leaves patients with few options for treatment, making it challenging to target and treat. 

Recently approved by the Food and Drug Administration, Pluvicto is a radionuclide-labelled drug administered to patients through a vein once every six weeks for six sessions. 

It provides targeted-radiation to these cancer cells, aiming to stabilize or reduce the size of metastases throughout the body, and in some cases, eliminate cancer cells altogether. 

The radioactive Lutitium-177 bound to PSMA-ligand-617 binds onto the prostate specific membrane antigen expressed by cancer cells, delivering the radioactive drug directly into what’s metastasized.

Positron emission tomography scans can help identify whether the prostate cancer has these prostate specific membrane antigen receptors and accurately depict where the cancer has metastasized to.

Once the metastases have been located and confirmed to have prostate specific membrane antigen receptor expression, a patient can begin Pluvicto treatments.

“Pluvicto is effective and well-tolerated for prostate cancer that is inoperable and has metastasized into the bones and other sites, and indicated for patients that have exhausted most of the standard care options for treatment of their cancer,” said Ka Kit Wong, MBBS, a clinical professor of nuclear medicine at University of Michigan Health who’s the director of the Therapy Nuclear Medicine Clinic.

“The treatment has mild side effects, although we monitor the blood counts and kidney function closely while the patient receives Pluvicto. This gives the patient the ability to continue their daily life routines fairly uninterrupted although some simple distance radiation precautions are followed for a short time with each treatment.”

Patients receiving Pluvicto will have regular measurement of their cancer biomarker on blood testing the prostate-specific antigen levels to ensure their treatment is proceeding appropriately.

Patients also need to meet requirements for blood count, kidney function and general mobility prior to receiving Pluvicto treatment, which is fulfilled through a series of lab testing around two weeks prior to each treatment.

“So far, Pluvicto is showing positive response in the PSA levels for a group of patients (as described in the landmark VISION trial) and in some quite dramatic responses,” said Wong

“However, one thing that is important is to try to get the treatment started earlier in the disease course, as waiting too long when the metastases have spread too much in the body makes it difficult to administer this treatment in a safe manner.”

The most common side effects of Pluvicto include fatigue, dry mouth, nausea, decreased appetite and constipation.

Get more information about Pluvicto.


More Articles About:

Prostate Cancer Prostate Conditions Cancer Research Cancer Treatment Radiation Oncology Interventional Radiology
Health Lab word mark overlaying blue cells

Health Lab

Explore thousands of health news & research stories by visiting the Health Lab homepage for more.

Media Contact

University Hospital at U-M Health in the spring with flowering trees in foreground and Survival Flight helicopter visible

Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe

Featured News & Stories

Man sits in a medical exam room looking at caregiver whose back is to camera and looks toward a computer screen.
Health Lab

Updated prostate cancer screening guidelines emphasize benefits of early detection

New guidelines for prostate cancer screening focus on early detection and individual risk.
Blue and yellow illustration of DNA helix
Health Lab

New anti-cancer strategy shows promise in preclinical studies

New cancer therapeutic strategy rewires protein interactions to improve efficacy and reduce potential side effects.
Group of men smiling in a field
News Release

How have diagnostic and treatment decisions for prostate cancer changed in recent years?

An analysis of United States data reveals a broad shift away from overtreatment of low-risk prostate cancer. The analysis by University of Michigan Rogel Cancer Center researchers, indicates a shift toward surveillance in response to concerns of overdiagnosis and overtreatment that have hindered screening in the recent past.
Family with mom and dad and three kids sitting on a park bench, dad's arms extended around the family.
Health Lab

Intuition pushed mom to keep checking for breast cancer

Michigan mom had no reason to suspect cancer. But instinct nudged her to find out for sure — and carried her through challenging treatments to remission.
Perforin increases endosomal-mitochondrial contact sites in tumor cells. Left is without perforin; right has perforin.
Health Lab

Immune system protein is a cancer killer on its own, new study shows

New study finds perforin can kill cancer tumor cells even when major granzymes were missing.
Three people stand arm in arm with backs to camera studying a wall of family mementos
Health Lab

Online resources and coaching helped people seek genetic testing for cancer

New study from researchers at the University of Michigan Rogel Cancer Center showed an online resource and phone-based coaching both helped increase rates of genetic testing.